论文部分内容阅读
[目的]评价老年晚期非小细胞肺癌(NSCLC)患者吉西他滨联合奥沙利铂化疗的疗效及耐受性。[方法]以吉西他滨联合奥沙利铂治疗老年晚期NSCLC58例,观察其化疗疗效、生活质量、不良反应及耐受性。[结果]治疗总有效率50.0%,其中初治者有效率59.1%,复治者为21.4%,中位生存期9.8个月。不良反应发生率小且较轻微,主要为骨髓抑制和胃肠道反应,其中白细胞减少65.5%,血小板减少58.6%,恶心、呕吐43.1%,多为轻度,均可耐受。[结论]老年晚期NSCLC用吉西他滨联合奥沙利铂治疗能取得较好的疗效,缓解症状,改善生活质量,不良反应轻,可以耐受。
[Objective] To evaluate the efficacy and tolerability of gemcitabine and oxaliplatin in elderly patients with advanced non-small cell lung cancer (NSCLC). [Method] Fifty-five elderly patients with advanced NSCLC were treated with gemcitabine plus oxaliplatin, and the curative effect, quality of life, adverse reactions and tolerability were observed. [Results] The total effective rate of treatment was 50.0%, of which the effective rate was 59.1% in primary treatment, 21.4% in retreatment, and the median survival was 9.8 months. The incidence of adverse reactions was small and minor, mainly myelosuppression and gastrointestinal reactions, including leukopenia 65.5%, thrombocytopenia 58.6%, nausea and vomiting 43.1%, mostly mild, can be tolerated. [Conclusion] Gemcitabine combined with oxaliplatin in elderly patients with advanced NSCLC can achieve better curative effect, relieve symptoms and improve quality of life, with less adverse reactions and tolerability.